We have shown that thalidomide (Thal) and its immunomodulatory derivatives (IMiDs), proteasome inhibitor PS-341, and As 2 O 3 act directly on multiple myeloma (MM) cells and in the bone marrow (BM) milieu to overcome drug resistance. Although Thal/IMiDs, PS-341, and As 2 O 3 inhibit nuclear factor (NF)-κB activation, they also have multiple and varied other actions. In this study, we therefore specifically address the role of NF-κB blockade in mediating anti-MM activity. In order to characterize the effect of specific NF-κB blockade on MM cell growth and survival in vitro, we used an IκB kinase (IKK) inhibitor (PS-1145).
INTRODUCTION
). IL-6 (20 ng/ml) overcomes the effect of IMiD3; importantly, however, PS-1145 neutralizes the inhibitory effect of IL-6 against IMiD3. These studies suggest that NF-κB blockade can overcome resistance to
IMiDs.
PS-1145 inhibits TNFα-induced ICAM-1 expression and enhances TNFα-induced apoptosis in MM.1S cells. We have previously shown that TNFα induces ICAM-1 and VCAM-1 expression on both BMSCs and MM cells, and that proteasome inhibitor PS-341 blocks
induction of these molecules (9) . Since PS-341 is not a specific NF-κB inhibitor, we cannot conclude from these earlier studies that TNFα-induced upregulation of ICAM-1 and VCAM-1 is mediated through NF-κB. However, PS-1145 also inhibits TNFα-induced upregulation of ICAM-1 expression on MM.1S and RPMI8226 cells (Fig. 5A ). This result strongly suggests that upregulation of ICAM-1 by TNFα is mediated via activation of NF-κB.
We have previously shown that TNFα induces modest proliferation, but not apoptosis, in MM.1S cells (9) . In this study, we hypothesized that TNFα would induce apoptosis in 
IC50 (µM)
<0.1(88 nM) >100 >100 >100 >100 >100 >100 >100 
>100 >100 >100 >100 >100 >100 >100 
